On April 26, 2013, Carlos Bernal-Mizrachi, MD was elected to the American Society for Clinical Investigation for his outstanding scholarly achievement in biomedical research. The ASCI elects up to 80 new members each year for their significant research accomplishments from several hundred nominations of physician-scientists from the United States and abroad.
. . . who has accomplished meritorious original, creative,
and independent investigations in the clinical or allied sciences
of medicine and enjoys an unimpeachable moral standing
in the medical profession . . .
— from the ASCI bylaws —
Carlos Bernal-Mizrachi, MD Research Profile
The long-term goal of our laboratory is to determine the mechanism involved in the crosstalk between innate immunity and the development of metabolic syndrome and its vascular complications. We are particularly interested in understanding the mechanisms of the interactions between vitamin D signaling and endoplasmic reticular stress in critical tissues contributing to metabolic dysregulation. Recent work from our laboratory has identified potential mechanisms by which vitamin D regulates macrophage cholesterol metabolism and monocyte function in patients with diabetes. We have generated multiple mouse models with diet-induced vitamin D deficiency or genetically modified mice of vitamin D signaling in order to identify the role of this vitamin in vivo on endoplasmic reticulum function in different tissues. In addition, we explored the effect of different environmental conditions that program signaling pathways to regulate monocyte/macrophage differentiation and function in models of type 2 diabetes. Our findings in mice and in human innate immune cells have laid the groundwork for our active randomized controlled trials assessing the effects of vitamin D supplementation on blood pressure and on subclinical markers of cardiovascular disease in type 2 diabetics.